Agios Pharmaceuticals AGIO Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

PrecigenPGEN

——

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Market cap$2.16B+18.1%

Enterprise value$2.08B+15.2%

P/S32.7×-16.7×

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Agios Pharmaceuticals's cash cash equivalents and short term investments?: Agios Pharmaceuticals (AGIO) reported cash cash equivalents and short term investments of $1B in Q1 2026.
How has Agios Pharmaceuticals's cash cash equivalents and short term investments changed year-over-year?: Agios Pharmaceuticals's cash cash equivalents and short term investments decreased by 28.6% year-over-year, from $1.4B to $1B.